EBS
What one share of Emergent Biosolutions holds
Pharmaceutical Preparations
We are a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate and naturally occurring Public Health Threats (“PHTs”). Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio.
Emergent Biosolutions’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.21 |
|---|---|
| Profit | −$3.26 |
| Capex (buildings and equipment) | $0.22 |
| Free cash flow | $1.58 |
| Cash and investments | $2.72 |
| Debt | $11.34 |
| Book value | $6.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $9.91 | $1.13 | $1.55 | −$0.44 | — | $14.69 |
| 2017 | $11.15 | $1.71 | $1.09 | $3.05 | — | $18.47 |
| 2018 | $15.22 | $1.22 | $1.40 | −$0.59 | — | $19.74 |
| 2019 | $21.11 | $1.04 | $1.66 | $1.93 | — | $21.11 |
| 2020 | $29.32 | $5.68 | $2.64 | $7.34 | — | $27.32 |
| 2021 | $32.78 | $4.06 | $4.14 | $1.78 | — | $31.41 |
| 2022 | $22.31 | −$4.22 | $2.31 | −$2.99 | — | $27.70 |
| 2023 | $20.49 | −$14.85 | $1.01 | −$5.04 | — | $12.44 |
| 2024 | $19.69 | −$3.60 | $0.43 | $0.68 | — | $8.89 |
| 2025 | $13.10 | $0.93 | $0.24 | $2.77 | — | $10.03 |